Galderma is Great Place to Work-Certified! 79% of employees at Galderma say it is a great place to work compared to 57% of employees at a typical U.S.-based company.
Galderma has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China – the largest of its kind – exploring the evolving expectations and experiences of patients and HCPs with anti-wrinkle aesthetic treatments. As the dermatology category leader, this survey demonstrates Galderma’s commitment to advancing progress in this market, through robust clinical research, product performance, and practitioner support.
The United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings.
New research continues to deepen the field’s understanding of skin barrier biology, neuroimmune interactions, and inflammatory mechanisms. These scientific advances are exciting and can benefit from accessible, high‑quality platforms to translate them into clinical practice and improve patient outcomes. Keeping this in mind, this year’s SKIN annual summit expanded beyond its previous focus on atopic dermatitis and prurigo nodularis to encompass a broader spectrum of inflammatory skin diseases.
Galderma reports strong start to the year, delivering first quarter 2026 net sales of 1.473 billion USD, growing 25.5% at constant currency.
Galderma is launching the Regenerating Skin Nectar with TriHex+™, the newest innovation from Alastin, a leader in peptide-based regenerative skincare. This innovation underscores Galderma’s commitment to advancing peri-procedural skincare and empowering providers with science-based solutions designed to deliver exceptional aesthetic and procedural outcomes.
Galderma welcomes new data from two IITs, demonstrating the power of Sculptra – the first proven regenerative biostimulator – and the company’s versatile hyaluronic acid injectable Restylane range, in addressing the aesthetic changes associated with menopause and medication-driven weight loss, for the face and body. Data includes an analysis from a first-of-its-kind study evaluating optimal treatment sequencing to enhance women’s skin during menopause, and an evaluation of the cellular makeup of fat in the abdomen following medication-driven weight loss.
Galderma today announced the launch of ALASTIN Signature Practices, a new designation for dermatology, plastic surgery, and medical aesthetics practices that integrate ALASTIN’s comprehensive regenerative skincare portfolio into treatment planning and patient care. Colorado Springs Dermatology Clinic is the first ALASTIN Signature Practice, with additional Signature Practices planned across the United States in 2026.
Galderma has anounced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21. This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas. With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S. approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands, and the chin. Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalized, natural-looking outcomes that meet diverse patient needs.
Galderma presented the latest updates on its innovative cross-dermatology portfolio at the 2026 American Academy of Dermatology (AAD) Annual Meeting, from March 27-31 in Denver, Colorado. Twenty-two abstracts were presented, including late-breaking data and three oral presentations spanning Therapeutic Dermatology, Injectable Aesthetics, and Dermatological Skincare.
